Capital International Inc’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$46M Buy
363,947
+7,991
+2% +$1.05M 0.32% 78
2026
Q1
$49.6M Buy
355,956
+32,960
+10% +$4.62M 0.38% 68
2025
Q4
$39.6M Sell
322,996
-34,883
-10% -$4.24M 0.31% 87
2025
Q3
$39.7M Buy
357,879
+81,363
+29% +$9.25M 0.32% 85
2025
Q2
$30.7M Buy
276,516
+27,131
+11% +$2.89M 0.3% 90
2025
Q1
$27.9M Sell
249,385
-62,824
-20% -$6.48M 0.34% 87
2024
Q4
$28.8M Buy
312,209
+60,035
+24% +$5.41M 0.34% 86
2024
Q3
$21.1M Buy
252,174
+16,068
+7% +$1.23M 0.27% 104
2024
Q2
$16.2M Buy
236,106
+1,189
+0.5% +$79.3K 0.22% 123
2024
Q1
$17.2M Buy
234,917
+46,848
+25% +$3.6M 0.23% 121
2023
Q4
$15.2M Buy
188,069
+82,367
+78% +$6.41M 0.24% 122
2023
Q3
$7.92M Buy
105,702
+21,222
+25% +$1.63M 0.15% 148
2023
Q2
$6.51M Buy
84,480
+69,339
+458% +$5.53M 0.12% 167
2023
Q1
$1.26M Buy
15,141
+1,614
+12% +$134K 0.03% 243
2022
Q4
$1.16M Buy
13,527
+6,817
+102% +$540K 0.03% 250
2022
Q3
$414K Buy
+6,710
New +$423K 0.01% 274
2022
Q2
Sell
-32,863
Closed -$1.95M 292
2022
Q1
$1.95M Sell
32,863
-5,085
-13% -$325K 0.02% 242
2021
Q4
$2.75M Sell
37,948
-45,037
-54% -$3.1M 0.03% 240
2021
Q3
$5.8M Sell
82,985
-4,970
-6% -$349K 0.06% 192
2021
Q2
$6.06M Sell
87,955
-24,223
-22% -$1.62M 0.05% 196
2021
Q1
$7.25M Sell
112,178
-15,582
-12% -$1M 0.07% 187
2020
Q4
$7.44M Buy
127,760
+6,984
+6% +$421K 0.07% 176
2020
Q3
$7.63M Sell
120,776
-15,555
-11% -$1.08M 0.08% 157
2020
Q2
$10.5M Buy
136,331
+6,623
+5% +$508K 0.13% 135
2020
Q1
$9.7M Buy
129,708
+55,188
+74% +$3.81M 0.16% 116
2019
Q4
$4.84M Sell
74,520
-28,415
-28% -$1.85M 0.07% 137
2019
Q3
$6.52M Buy
+102,935
New +$6.73M 0.1% 131
2019
Q1
Sell
-290
Closed -$18K 184
2018
Q4
$18K Sell
290
-466
-62% -$32.6K ﹤0.01% 180
2018
Q3
$58K Sell
756
-7,174
-90% -$542K 0.01% 174
2018
Q2
$562K Sell
7,930
-100
-1% -$7.06K 0.09% 128
2018
Q1
$605K Buy
8,030
+400
+5% +$31.8K 0.09% 129
2017
Q4
$547K Sell
7,630
-4,820
-39% -$366K 0.08% 127
2017
Q3
$1.01M Sell
12,450
-800
-6% -$61.2K 0.15% 102
2017
Q2
$938K Sell
13,250
-7,670
-37% -$510K 0.13% 101
2017
Q1
$1.42M Hold
20,920
0.17% 97
2016
Q4
$1.5M Sell
20,920
-1,830
-8% -$136K 0.19% 99
2016
Q3
$1.8M Sell
22,750
-21,450
-49% -$1.74M 0.21% 81
2016
Q2
$3.69M Sell
44,200
-8,700
-16% -$772K 0.44% 44
2016
Q1
$4.86M Sell
52,900
-51,900
-50% -$4.68M 0.53% 39
2015
Q4
$10.6M Sell
104,800
-9,100
-8% -$947K 0.94% 33
2015
Q3
$11.2M Sell
113,900
-101,900
-47% -$11.3M 1.01% 28
2015
Q2
$25.3M Hold
215,800
1.81% 15
2015
Q1
$21.2M Sell
215,800
-138,200
-39% -$14M 1.59% 17
2014
Q4
$33.4M Sell
354,000
-236,900
-40% -$24.5M 2.28% 13
2014
Q3
$62.9M Sell
590,900
-125,300
-17% -$12.3M 3.92% 6
2014
Q2
$59.4M Sell
716,200
-236,600
-25% -$18.4M 3.13% 8
2014
Q1
$67.5M Sell
952,800
-101,900
-10% -$7.99M 2.98% 11
2013
Q4
$79.3M Sell
1,054,700
-154,400
-13% -$10.8M 3.41% 8
2013
Q3
$76M Sell
1,209,100
-1,572,500
-57% -$94M 3.37% 9
2013
Q2
$142M Buy
+2,781,600
New +$145M 5.18% 1

Other funds holding GILD

Capital International Inc's GILD Position: Q2 2026 in Review

Capital International Inc increased its Gilead Sciences (GILD) stake by 2.2% in Q2 2026, buying an estimated $1.05M and bringing the position to 363,947 shares worth $46M. The position accounts for 0.32% of the portfolio, ranked #78.

Capital International Inc first reported a position in GILD in Q2 2013 and has held it in 50 quarters since. The position peaked at $142M in Q2 2013. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Capital International Inc held 363,947 shares of Gilead Sciences worth $46M as of Q2 2026.
  • Capital International Inc bought 7,991 Gilead Sciences shares in Q2 2026, an estimated $1.05M.
  • Gilead Sciences made up 0.32% of Capital International Inc's portfolio in Q2 2026, its #78 holding.
  • Capital International Inc first reported a position in Gilead Sciences in Q2 2013 and has held it in 50 quarters since.
  • Capital International Inc's Gilead Sciences position peaked at $142M in Q2 2013.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Capital International Inc's 13F filing for Q2 2026, filed 12 Aug 2026.